FDA Publishes Draft Guidance on Responding to FDA Form 483 Observations At the Conclusion of a Drug CGMP Inspection | Covington & Burling LLP
How American capital pursuing Belgian investment or acquisition targets can mitigate deal‑breaker risks
Quarterly Merger Control Webinars: Recent upheaval in the US, new proposals for merger review in the UK, FDI and updates from Mexico
Getting ready for the EU Pharma Package: key changes to regulatory exclusivities, orphan medicinal products and the “Bolar” exemption provisions
New transparency regime for contractual control over land: what it means for developers and landowners in England and Wales
The European Banking Authority Issues Final Guidelines on Capital Endowment Requirements for Third-Country Branches Under CRD VI